@article {McGaraughty3616, author = {McGaraughty, Steve and Davis-Taber, Rachel A. and Zhu, Chang Z. and Cole, Todd B. and Nikkel, Arthur L. and Chhaya, Meha and Doyle, Kelly J. and Olson, Lauren M. and Preston, Gregory M. and Grinnell, Christine M. and Salte, Katherine M. and Giamis, Anthony M. and Luo, Yanping and Sun, Victor and Goodearl, Andrew D. and Gopalakrishnan, Murali and Lacy, Susan E.}, title = {Targeting Anti{\textendash}TGF-β Therapy to Fibrotic Kidneys with a Dual Specificity Antibody Approach}, volume = {28}, number = {12}, pages = {3616--3626}, year = {2017}, doi = {10.1681/ASN.2017010013}, publisher = {American Society of Nephrology}, abstract = {Targeted delivery of a therapeutic agent to a site of pathology to ameliorate disease while limiting exposure at undesired tissues is an aspirational treatment scenario. Targeting diseased kidneys for pharmacologic treatment has had limited success. We designed an approach to target an extracellular matrix protein, the fibronectin extra domain A isoform (FnEDA), which is relatively restricted in distribution to sites of tissue injury. In a mouse unilateral ureteral obstruction (UUO) model of renal fibrosis, injury induced significant upregulation of FnEDA in the obstructed kidney. Using dual variable domain Ig (DVD-Ig) technology, we constructed a molecule with a moiety to target FnEDA and a second moiety to neutralize TGF-β. After systemic injection of the bispecific TGF-β + FnEDA DVD-Ig or an FnEDA mAb, chemiluminescent detection and imaging with whole-body single-photon emission computed tomography (SPECT) revealed significantly higher levels of each molecule in the obstructed kidney than in the nonobstructed kidney, the ipsilateral kidney of sham animals, and other tissues. In comparison, a systemically administered TGF-β mAb accumulated at lower concentrations in the obstructed kidney and exhibited a more diffuse whole-body distribution. Systemic administration of the bispecific DVD-Ig or the TGF-β mAb (1{\textendash}10 mg/kg) but not the FnEDA mAb attenuated the injury-induced collagen deposition detected by immunohistochemistry and elevation in Col1a1, FnEDA, and TIMP1 mRNA expression in the obstructed kidney. Overall, systemic delivery of a bispecific molecule targeting an extracellular matrix protein and delivering a TGF-β mAb resulted in a relatively focal uptake in the fibrotic kidney and reduced renal fibrosis.}, issn = {1046-6673}, URL = {https://jasn.asnjournals.org/content/28/12/3616}, eprint = {https://jasn.asnjournals.org/content/28/12/3616.full.pdf}, journal = {Journal of the American Society of Nephrology} }